Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Shares IssuedShares OutstandingShares Outstanding
Ratios

Nuvectis Pharma (NVCT) Shares Outstanding (2021 - 2026)

Nuvectis Pharma has reported Shares Outstanding over the past 6 years, most recently at $26.5 million for Q1 2026.

  • Quarterly results put Shares Outstanding at $26.5 million for Q1 2026, up 12.23% from a year ago — trailing twelve months through Mar 2026 was $26.5 million (up 12.23% YoY), and the annual figure for FY2025 was $25.7 million, up 31.71%.
  • Shares Outstanding reached $26.5 million in Q1 2026 per NVCT's latest filing, up from $25.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $26.5 million in Q1 2026 and bottomed at $12.7 million in Q1 2022.
  • Median Shares Outstanding over the past 5 years was $18.4 million (2024), compared with a mean of $19.1 million.
  • The largest annual shift saw Shares Outstanding surged 226.1% in 2022 before it increased 8.87% in 2024.
  • Over 5 years, Shares Outstanding stood at $15.2 million in 2022, then grew by 14.67% to $17.4 million in 2023, then grew by 11.92% to $19.5 million in 2024, then surged by 31.71% to $25.7 million in 2025, then rose by 3.31% to $26.5 million in 2026.
  • Business Quant data shows Shares Outstanding for NVCT at $26.5 million in Q1 2026, $25.7 million in Q4 2025, and $25.6 million in Q3 2025.